Close
Almac
Achema middle east

Science organisations collaborate to create North East bioscience hub

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

CPI, FUJIFILM Diosynth Biotechnologies and Teesside University announced a collaboration to accelerate the bioscience sector in the Tees Valley Region. Named the Northern Bio-Accelerator Partnership (NBioP), the new collaboration will create a bioprocessing, biomanufacturing and biopharmaceutical hub in the region. This will position the North East as a centre of innovation, attracting investment, enhanced education and workforce development, ultimately enabling more companies to bring life changing medicines to market faster.

Based at Darlington’s Central Park, with easy access to rail, road and air travel, the hub will provide a unique location to attract investment and skills from across the North East and beyond.

Each organisation brings unique expertise to the partnership, with a proven track record of collaboration. Teesside University, through its National Horizons Centre, will provide the academic and skills aspect, offering industry-specific scientific expertise, while also driving research and providing workforce training and development. CPI will leverage its existing industry connections, innovation facilities and expertise to reduce risk, gain investment and accelerate the development of new biotech products and their manufacturing processes. FUJIFILM Diosynth Biotechnologies, a global leader in the contract development and manufacture of biologics, will bring its global expertise for the development of new tools and technologies for biopharmaceutical manufacturing applications. This complementary approach is truly unique, with a focus not only on industry growth but also on education and employment opportunities in the region.

Having a ready workforce is more critical than ever, as researchers work on a COVID-19 vaccine. The skillset required for vaccine manufacturing and the production of other biotherapeutics requires in depth bioprocessing knowledge. Through this partnership and a joint training offering, the hub is already creating a pipeline of graduate talent, helping to train the next generation workforce in areas including advanced therapies.

With a high-density cluster of expertise and a well-developed business ecosystem, the North East offers a bioscience community that is second to none in the UK. Access to a mature supply chain and highly-skilled workforce, with much lower business costs than other areas of the UK, means a start-up company can establish itself in the region for life. In addition, start-ups can develop alongside other companies, collaborating with them throughout their business development lifecycle.

Frank Millar, CEO at CPI, said: “The North East has a thriving biosciences sector that is globally competitive, vibrant and viable. This collaboration will enable us to draw on the best of research, workforce development, innovation and manufacturing to enable companies to develop, prove, scale up and manufacture new products that will improve the quality of life of people around the world.”

Dr Mark Douglas, vice president at FUJIFILM Diosynth Biotechnologies, said: “We are very pleased to be a partner in this exciting collaboration and look forward to developing innovative new technologies here in Teesside, to address biopharmaceutical manufacturing challenges at a global level.”

Dr Jen Vanderhoven, director of the National Horizons Centre at Teesside University, said: “This new collaboration will build on the strong industrial heritage, and burgeoning Tees Valley life sciences sector to enable staff, students and industry partners to work together. Drawing upon each other’s expertise and experiences, we will catalyse economic growth in the North East through the creation of jobs, the training of a highly skilled workforce and the driving of the nationally leading biosciences research and development.”

Ben Houchen, Tees Valley Mayor, said: “Our region is becoming one of the best places in the world for science, innovation and jobs of the future, and this is down to the fantastic work being done behind the scenes at the National Horizons Centre, CPI and Fujifilm Diosynth Biotechnologies. Science and innovation are thriving in our region, and we’ve all seen this year how important work is on future medicines and therapies. It is because of nationally significant partnerships like this that we can continue to punch above our weight as a region and attract jobs, businesses and investment to Teesside, Darlington and Hartlepool.”

CPI works with partners to translate inventions into products and processes that enhance health and wellbeing, protect and improve our environment and increase productivity across industries.

FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark.

The National Horizons Centre (NHC), established by Teesside University, is an exciting £22 million biosciences research, teaching and training facility. Sitting at the heart of a cluster of excellence on Darlington’s Central Park alongside the National Biologics Manufacturing Centre (NBMC) and the Centre for Professional and Executive Development, in the North East of England.

Latest stories

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »